these data suggest that igiv prepared by chemical modification retains sufficient specific receptor activity to allow in vivo efficacy in complement-mediated amplification of host defense reactions , but is safe for intravenous use due to a lower capacity to initiate nonspecific complement activation .
C0009498
complement
C0009528
complement activation